Immunogenicity and safety of V260 [rotavirus W179-9 vaccine] in healthy infants in Korea.

Next Previous
Trial Profile

Immunogenicity and safety of V260 [rotavirus W179-9 vaccine] in healthy infants in Korea.

Completed
Phase of Trial: Phase III

Latest Information Update: 09 Jun 2014

At a glance

  • Drugs Rotavirus W179-9 vaccine (Primary)
  • Indications Rotavirus infections
  • Focus Pharmacodynamics
  • Sponsors Merck & Co

    • Most Recent Events

    • 16 Mar 2009 Actual patient number changed from 177 to 178 as reported by ClinicalTrials.gov.
    • 01 Oct 2008 Additional trial identifier (V260-013) reported by ClinicalTrials.gov.
    • 01 Oct 2008 Additional trial identifier (V260-013) reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top